INSM Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of -39.75%. Insmed, Inc.'s return on equity of -193.23% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Insmed, Inc. has a consensus price target of $215.28, signalling upside risk potential of 29.26%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 6.44%. Given that Insmed, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Insmed, Inc.'s net income of -$370M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 70.88x versus 16.30x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 21.32%. Insmed, Inc.'s return on equity of -193.23% beat Pfizer Inc.'s return on equity of 10.84%.

Insmed, Inc. has a consensus price target of $215.28, signalling upside risk potential of 29.26%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.31%. Given that Insmed, Inc. has higher upside potential than Pfizer Inc., analysts believe Insmed, Inc. is more attractive than Pfizer Inc..

Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Insmed, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Insmed, Inc.'s net income of -$370M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 70.88x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 42.36%. Insmed, Inc.'s return on equity of -193.23% beat United Therapeutics Corp.'s return on equity of 19.2%.

Insmed, Inc. has a consensus price target of $215.28, signalling upside risk potential of 29.26%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 1.43%. Given that Insmed, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Insmed, Inc. is more attractive than United Therapeutics Corp..

Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $142.3M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Insmed, Inc.'s net income of -$370M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while United Therapeutics Corp.'s PE ratio is 19.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 70.88x versus 7.88x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 34.76%. Insmed, Inc.'s return on equity of -193.23% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Insmed, Inc. has a consensus price target of $215.28, signalling upside risk potential of 29.26%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $489.48 which suggests that it could grow by 8.89%. Given that Insmed, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Insmed, Inc.'s net income of -$370M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 70.88x versus 9.93x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.